New pill tested for Tough-to-Treat lung cancer
NCT ID NCT06186076
Summary
This early-stage study tested a new oral drug called TRX-221 for people with advanced lung cancer driven by an EGFR gene mutation, whose disease worsened after standard treatments. The main goals were to find a safe dose and see if the drug could shrink tumors. The trial was terminated early and enrolled only 19 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Chungbuk National University Hospital
Chungju, North Chungcheong, 28644, South Korea
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam, Kyeongki, 13620, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
The Catholic University of Korea St. Vincent Hospital
Suwon, Kyeongki, 16247, South Korea
Conditions
Explore the condition pages connected to this study.